SCHEMBL5263941

SCHEMBL5263941

Cc1cccc(N2CCN(CCc3[nH]n(-c4ccccc4)c(=O)c3Cl)CC2)c1C

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
ALDH1A1 P00352 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.54
HTR2A P28223 7/20 0.45
HTR2C P28335 7/20 0.45
SLC6A4 P31645 5/20 0.45
HTR1A P08908 2/20 0.45
DRD2 P14416 2/20 0.45
ADRA1D P25100 2/20 0.45
ADRA1A P35348 2/20 0.45
ADRA1B P35368 2/20 0.45
DRD1 P21728 1/20 0.45
HTR7 P34969 3/20 0.44
TP53 P04637 2/20 0.43
MAPT P10636 1/20 0.43
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264352 0.94 SMN1; SMN2 (0.55) MEN1ALDH1A1KMT2ASMN1; SMN2HTR2A
SCHEMBL5264783 0.86 DRD2 (0.51) HTR2ASLC6A4HTR1ADRD2DRD1
SCHEMBL5270524 0.86 MEN1 (0.54) MEN1ALDH1A1KMT2ASMN1; SMN2HTR1A
SCHEMBL5270523 0.85 ADRA1B (0.54) MEN1ALDH1A1KMT2ASLC6A4HTR1A
SCHEMBL5265422 0.84 ADRA1D (0.57) MEN1KMT2AHTR2CHTR1ADRD2
SCHEMBL5265027 0.82 DRD4 (0.47) HTR2AHTR2CSLC6A4HTR1ADRD2
SCHEMBL5266680 0.81 SLC6A2 (0.47) SLC6A4HTR1ADRD2HTR7
SCHEMBL5268778 0.81 MEN1 (0.48) MEN1KMT2AHTR1ADRD2HTR7
SCHEMBL5262999 0.80 DRD2 (0.54) HTR2ASLC6A4HTR1ADRD2DRD1
SCHEMBL5265038 0.79 OPRM1 (0.54) HTR1ADRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed